Skip to main content
Design Therapeutics, Inc. logo

Design Therapeutics, Inc. — Investor Relations & Filings

Ticker · DSGN ISIN · US25056L1035 US Manufacturing
Open in API
Filings indexed 242 across all filing types
Latest filing 2021-08-09 Report Publication Anno…
Country US United States of America
Listing US DSGN

About Design Therapeutics, Inc.

https://www.designtx.com/

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a new class of small molecule therapies for genetic diseases. The company's proprietary GeneTAC® (Gene Targeted Chimera) platform is used to design therapeutic candidates that target the underlying cause of genetic disorders. These molecules are engineered to modulate gene expression—either increasing or decreasing it as needed—without requiring gene editing. The company's initial focus is on monogenic diseases driven by nucleotide repeat expansions, with programs targeting conditions such as Friedreich ataxia, myotonic dystrophy, Fuchs endothelial corneal dystrophy, and Huntington’s disease. The company aims to develop functional cures for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K
Report Publication Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 9, 2021, reporting the issuance of a press release announcing financial results for the three and six months ended June 30, 2021. The text explicitly states that the press release is attached as Exhibit 99.1 and that the information is being furnished and not filed, indicating this document is an announcement of financial results rather than the results themselves. The document length is 3492 characters, which is relatively short and consistent with a report publication announcement rather than a full financial report. There are no actual financial statements or substantive financial data included in the text, only a reference to the press release. Therefore, according to the MENU VS MEAL RULE and the CERTIFICATION RULE, this document should be classified as a Report Publication Announcement (RPA).
2021-08-09 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 2, 2021, reporting a change in the company's principal accounting officer and a resignation of a VP, Finance. The content focuses on management changes, specifically the departure and appointment of officers. There is no financial data or report attached, nor is it an announcement of a report publication. The document fits the category of Board/Management Information (MANG) as it announces changes in senior management positions.
2021-08-06 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-16 English
FORM 3 SUBMISSION
Director's Dealing
2021-06-16 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-16 English
FORM 3 SUBMISSION
Director's Dealing
2021-06-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.